Antikoagülan Tedavi ve Antikoagülasyonun Tersine Çevrilmesi

Reversal of antithrombotic agents. (yeni pencere açar)

Bauer KA.

Kaynak‎: Am J Hematol 2012;87 Suppl 1:S119-26.

İndeks‎: PubMed 22460529

DOI‎: 10.1002/ajh.23165

https://www.ncbi.nlm.nih.gov/pubmed/22460529 (yeni pencere açar)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (yeni pencere açar)

Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M

Kaynak‎: J Thromb Haemost 2015;13(10):1790-8.

İndeks‎: PubMed 26270886

DOI‎: 10.1111/jth.13117

https://www.ncbi.nlm.nih.gov/pubmed/26270886 (yeni pencere açar)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (yeni pencere açar)

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators

Kaynak‎: N Engl J Med 2019;380(14):1326-35.

İndeks‎: PubMed 30730782

DOI‎: 10.1056/NEJMoa1814051

https://www.ncbi.nlm.nih.gov/pubmed/30730782 (yeni pencere açar)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (yeni pencere açar)

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators

Kaynak‎: N Engl J Med 2016;375(12):1131-41.

İndeks‎: PubMed 27573206

DOI‎: 10.1056/NEJMoa1607887

https://www.ncbi.nlm.nih.gov/pubmed/27573206 (yeni pencere açar)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (yeni pencere açar)

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M

Kaynak‎: Circulation 2011;124(14):1573-9.

İndeks‎: PubMed 21900088

DOI‎: 10.1161/CIRCULATIONAHA.111.029017

https://www.ncbi.nlm.nih.gov/pubmed/21900088 (yeni pencere açar)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (yeni pencere açar)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Kaynak‎: Lancet 2015;385(9982):2077-87.

İndeks‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (yeni pencere açar)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (yeni pencere açar)

Gordon JL, Fabian TC, Lee MD, Dugdale M

Kaynak‎: J Trauma Acute Care Surg 2013;75(3):475-86.

İndeks‎: PubMed 24089118

DOI‎: 10.1097/TA.0b013e3182a07391

https://www.ncbi.nlm.nih.gov/pubmed/24089118 (yeni pencere açar)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (yeni pencere açar)

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Kaynak‎: Am J Hematol 2012;87 Suppl 1:S141-5.

İndeks‎: PubMed 22473649

DOI‎: 10.1002/ajh.23202

https://www.ncbi.nlm.nih.gov/pubmed/22473649 (yeni pencere açar)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (yeni pencere açar)

Levi M, Eerenberg E, Kamphuisen PW.

Kaynak‎: J Thromb Haemost 2011;9(9):1705-12.

İndeks‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (yeni pencere açar)

Emergency reversal of warfarin anticoagulation. (yeni pencere açar)

Lin Y, Callum J.

Kaynak‎: CMAJ 2010;182(18):2004.

İndeks‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (yeni pencere açar)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (yeni pencere açar)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Kaynak‎: Thromb Haemost 2012;108(2):217-24.

İndeks‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (yeni pencere açar)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (yeni pencere açar)

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Kaynak‎: J Thromb Haemost 2008;6(4):622-31.

İndeks‎: PubMed 18208533

DOI‎: 10.1111/j.1538-7836.2008.02904.x

https://www.ncbi.nlm.nih.gov/pubmed/18208533 (yeni pencere açar)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (yeni pencere açar)

Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R

Kaynak‎: Blood Adv 2019;3(2):158-67.

İndeks‎: PubMed 30658963

DOI‎: 10.1182/bloodadvances.2018024133

https://www.ncbi.nlm.nih.gov/pubmed/30658963 (yeni pencere açar)

Idarucizumab for dabigatran reversal. (yeni pencere açar)

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Kaynak‎: N Engl J Med 2015;373(6):511-20.

İndeks‎: PubMed 26095746

DOI‎: 10.1056/NEJMoa1502000

https://www.ncbi.nlm.nih.gov/pubmed/26095746 (yeni pencere açar)

Idarucizumab for dabigatran reversal - full cohort analysis. (yeni pencere açar)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Kaynak‎: N Engl J Med 2017;377(5):431-41.

İndeks‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (yeni pencere açar)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (yeni pencere açar)

Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B

Kaynak‎: Blood 2003;102(13):4594-9.

İndeks‎: PubMed 12920042

DOI‎: 10.1182/blood-2002-11-3566

https://www.ncbi.nlm.nih.gov/pubmed/12920042 (yeni pencere açar)

Role of agents for reversing the effects of target-specific oral anticoagulants. (yeni pencere açar)

Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS

Kaynak‎: Am J Health Syst Pharm 2017;74(2):54-61.

İndeks‎: PubMed 27895055

DOI‎: 10.2146/ajhp150810

https://www.ncbi.nlm.nih.gov/pubmed/27895055 (yeni pencere açar)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (yeni pencere açar)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Kaynak‎: Anesth Analg 2011;113(4):703-10.

İndeks‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (yeni pencere açar)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (yeni pencere açar)

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS

Kaynak‎: J Am Coll Cardiol 2017;70(24):3042-67.

İndeks‎: PubMed 29203195

DOI‎: 10.1016/j.jacc.2017.09.1085

https://www.ncbi.nlm.nih.gov/pubmed/29203195 (yeni pencere açar)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (yeni pencere açar)

Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, Pombra J, Akins PT, Axelrod YK, Ge IY, Sheridan WF, Flint AC.

Kaynak‎: World Neurosurg 2014;81(1):110-5.

İndeks‎: PubMed 23220122

DOI‎: 10.1016/j.wneu.2012.12.002

https://www.ncbi.nlm.nih.gov/pubmed/23220122 (yeni pencere açar)

Reversal of warfarin-induced hemorrhage in the emergency department. (yeni pencere açar)

Zareh M, Davis A, Henderson S.

Kaynak‎: West J Emerg Med 2011;12(4):386-92.

İndeks‎: PubMed 22224125

DOI‎: 10.5811/westjem.2011.3.2051

https://www.ncbi.nlm.nih.gov/pubmed/22224125 (yeni pencere açar)

YOĞUN BAKIM

Antikoagülan Tedavi ve Antikoagülasyonun Tersine Çevrilmesi

Türkçe

Antikoagülan Tedavi ve Antikoagülasyonun Tersine Çevrilmesi

https://assetsnffrgf-a.akamaihd.net/assets/ct/e781f8601f/images/syn_placeholder_sqr.png

Antikoagülan Tedavi ve Antikoagülasyonun Tersine Çevrilmesi

Reversal of antithrombotic agents. (yeni pencere açar)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (yeni pencere açar)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (yeni pencere açar)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (yeni pencere açar)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (yeni pencere açar)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (yeni pencere açar)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (yeni pencere açar)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (yeni pencere açar)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (yeni pencere açar)

Emergency reversal of warfarin anticoagulation. (yeni pencere açar)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (yeni pencere açar)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (yeni pencere açar)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (yeni pencere açar)

Idarucizumab for dabigatran reversal. (yeni pencere açar)

Idarucizumab for dabigatran reversal - full cohort analysis. (yeni pencere açar)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (yeni pencere açar)

Role of agents for reversing the effects of target-specific oral anticoagulants. (yeni pencere açar)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (yeni pencere açar)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (yeni pencere açar)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (yeni pencere açar)

Reversal of warfarin-induced hemorrhage in the emergency department. (yeni pencere açar)

Hastane İrtibat Heyeti Yerel Temsilcisiyle İletişime Geçin

Tıbbi Bilgilendirme Paketleri

Videolar

Antikoagülan Tedavi ve Antikoagülasyonun Tersine Çevrilmesi

Dilinizi Seçin

Paylaş